NCT05698524 A Study of Temodar With Abexinostat (PCI-24781) for Patients With Recurrent Glioma
| NCT ID | NCT05698524 |
| Status | Recruiting |
| Phase | Phase 1 |
| Sponsor | University of Nebraska |
| Condition | Recurrent High Grade Glioma |
| Study Type | INTERVENTIONAL |
| Enrollment | 24 participants |
| Start Date | 2023-06-26 |
| Primary Completion | 2027-07 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 1 is the earliest stage of human testing — safety and dosage are the primary focus. Visits are frequent and medical supervision is intensive. You will be among the first people to receive this treatment.
This trial targets 24 participants in total. It began in 2023-06-26 with a primary completion date of 2027-07.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Glioblastoma (GBM), WHO grade IV glioma, represents the majority of adult malignant primary brain tumors, with an incidence of 2-3 per 100,000 person-years. The survival for GBM has increased in the last decade but is still low with a median survival of 15-18 months. Recurrence after initial standard therapy, radiation therapy and chemotherapy with temozolomide, few options are available. Even with further therapy, median progression free survival at 6 months after first relapse (PFS-6) is only 15%. Similarly, anaplastic astrocytoma and anaplastic oligodendroglioma, grade III gliomas, once recurrent after radiation therapy and first-line chemotherapy, have identical therapeutic options and poor outcomes with PFS-6 of 31%. Temozolomide (TMZ) has a favorable side effect profile and is available orally, however, cytotoxicity occurs. Metronomic temozolomide at low doses on a continuous schedule, have demonstrated better survival in studies. This study will determine the recommended dose and the side effects of PCI-24781/Abexinostat with metronomic temozolomide.
Eligibility Criteria
Inclusion Criteria: * Pathologically proven diagnosis of high grade (aka grade III or IV) glioma (anaplastic astrocytoma, anaplastic oligodendroglioma, glioblastoma, gliosarcoma) * Prior radiation therapy and standard temozolomide; additional therapies for previous progressions are eligible (prior bevacizumab and Optune are allowed) * Three or more months from the end of chemoradiotherapy or have biopsy or imaging consistent with disease progression * 19 years of age or older (the age of consent in Nebraska) * Fully recovered from any toxicity of prior therapy that, in the opinion of the investigator, could impact tolerance to the study drug * Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-2 * Adequate bone marrow reserve (ANC count ≥1,500/mm3, hemoglobin \> 8 g/dL, platelet count ≥100,000/mm3) * Adequate renal function (a serum creatinine that is at or below 2.0 mg/dL) * Adequate hepatic function (serum AST and ALT less than 1.5 times the upper limits of normal, serum alkaline phosphatase less than 2.5 times the upper limits of normal) * Able to provide written, informed consent * Females of child-bearing potential must have a negative pregnancy test within 7 days of initiating study (non-child bearing potential is defined as age 55 years or older and no menses for two years or any age with surgical removal of the uterus and/or both ovaries) * Females of reproductive potential must agree to employ an effective barrier method of birth control throughout the study and up to 6 months following treatment Exclusion Criteria: * Any life-threatening illness, medical condition, or organ system dysfunction which, in the investigator's opinion, could compromise the subject's safety, interfere with the absorption or metabolism of oral PCI-24781/Abexinostat, or put the study outcomes at undue risk * Significant cardiovascular disease such as uncontrolled or symptomatic arrhythmia, congestive heart failure, or myocardial infarction within 6 months of screening, or any Class 3 or 4 cardiac disease as defined by the New York Heart Association Functional Classification * Malabsorption syndrome, disease significantly affecting gastrointestinal function, or resection of the stomach or small bowel or ulcerative colitis, symptomatic inflammatory bowel disease, or partial or complete bowel obstruction * Immunotherapy, chemotherapy, radiotherapy, corticosteroids (at dosages equivalent to prednisone \> 20 mg/day) or experimental therapy (other than PCI-24781/Abexinostat PO) within 4 weeks before first dose of study drug * Concurrent use of enzyme-inducing antiepileptic drugs (phenytoin, phenobarbital, carbamazepine, felbamate, topiramate and oxcarbazepine) * Any other active malignancy other than nonmelanoma skin cancer or controlled prostate cancer * Known history of Human Immunodeficiency Virus (HIV) or active infection with Hepatitis C Virus (HCV) or Hepatitis B Virus (HBV) or any uncontrolled active systemic infection (no testing is required for eligibility) * Creatinine \> 1.5 x institutional upper limit of normal (ULN); total bilirubin \> 1.5 x ULN (unless from Gilbert's disease), and aspartate aminotransferase (AST) or alanine aminotransferase (ALT) \> 2.5 x ULN * Pregnant or breast-feeding * Baseline ECG duration of the ventricular action potential corrected for heart rate (QTc interval) prolongation based on Fridericia's formula is \> 450 ms in males and \> 470 ms in females * Concomitant valproic acid use, or another histone deacetylases (HDAC) inhibitor * Receiving treatment with following medications and unable to discontinue treatment or switch medications prior to study enrollment: * Amiodarone (Cordarone, Pacerone) * Arsenic trioxide (Trisenox) * Chlorpromazine (Aralen) * Cisapride (Propulsid) * Clarithromycin (Biaxin) * Disopyramide (Norpace) * Dofetilide (Tikosyn) * Doperidol (Inapsine) * Erythromycin (EryTab, Erythrocin) * Flecanide (Tambocor) * Haloperidol (Haldol) * Ibutilide (Corvert) * Methadone (Methadose, Dolophine) * Moxifloxacin (Avelox) * Pentamidine (Pentam, Nebupent) * Pimozide (Orap) * Procainamide (Procan, Pronestyl) * Quinidine (Cardioquin, Quinaglute) * Sotalol (Betapace) * Thioridazine (Mellaril) * Vandetanib (Zactima)
Contact & Investigator
Nicole A Shonka, MD
PRINCIPAL INVESTIGATOR
University of Nebraska
Frequently Asked Questions
Who can join the NCT05698524 clinical trial?
This trial is open to participants of all sexes, aged 19 Years or older, studying Recurrent High Grade Glioma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT05698524 trial and what does that mean for participants?
Phase 1 trials are the first stage of human testing. The primary goal is to assess safety and determine appropriate dosage levels. Participants are closely monitored. These trials typically involve a small number of volunteers.
Is NCT05698524 currently recruiting?
Yes, NCT05698524 is actively recruiting participants. Contact the research team at misavine@unmc.edu for enrollment information.
Where is the NCT05698524 trial being conducted?
This trial is being conducted at Omaha, United States.
Who is sponsoring the NCT05698524 clinical trial?
NCT05698524 is sponsored by University of Nebraska. The principal investigator is Nicole A Shonka, MD at University of Nebraska. The trial plans to enroll 24 participants.